Olanzapine in the treatment of depressive disorders with psychotic symptoms

被引:18
作者
Adli, M [1 ]
Rossius, W [1 ]
Bauer, M [1 ]
机构
[1] Free Univ Berlin, Psychiat Klin & Poliklin, D-14050 Berlin, Germany
来源
NERVENARZT | 1999年 / 70卷 / 01期
关键词
combined neuroleptic/antidepressant treatment; depression; neuroleptics; olanzapine; receptor-binding profile; therapy resistance;
D O I
10.1007/s001150050402
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We report on the successful treatment of two female patients with psychotic depression with the new atypical neuroleptic drug olanzapine. A 75-year-old female in patient suffering from recurrent endogenous depression with tactile hallucinations and co-enesthesia was refractory to a systematic sequential antidepressant treatment strategy during a 39-week period. After addition of the new atypical neuroleptic olanzapine to the SSRI citalopram, she showed immediate and ongoing symptom relief. In the second case of a 57-year-old female inpatient suffering from delusional depression,we observed marked symptom relief and correction of the delusions of impoverishment. Olanzapine is discussed with regard to its receptor-binding profile (antagonism to 5-HT2A- and D1-D4 receptors) as a potential neuroleptic drug in the treatment of affective disorders with psychotic symptoms.
引用
收藏
页码:68 / 71
页数:4
相关论文
共 17 条
[1]   RELAPSE IN DELUSIONAL DEPRESSION - A RETROSPECTIVE STUDY OF THE COURSE OF TREATMENT [J].
ARONSON, TA ;
SHUKLA, S ;
GUJAVARTY, K ;
HOFF, A ;
DIBUONO, M ;
KHAN, E .
COMPREHENSIVE PSYCHIATRY, 1988, 29 (01) :12-21
[2]  
BANOV MD, 1994, J CLIN PSYCHIAT, V55, P295
[3]   Radioreceptor binding profile of the atypical antipsychotic olanzapine [J].
Bymaster, FP ;
Calligaro, DO ;
Falcone, JF ;
Marsh, RD ;
Moore, NA ;
Tye, NC ;
Seeman, P ;
Wong, DT .
NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) :87-96
[4]   Olanzapine - A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses [J].
Fulton, B ;
Goa, KL .
DRUGS, 1997, 53 (02) :281-298
[5]  
Glazer WM, 1997, J CLIN PSYCHIAT, V58, P18
[6]  
MAVROGIORGOU P, 1997, THERAPIERESISTENCE D, P119
[7]  
MCELROY SL, 1991, J CLIN PSYCHIAT, V52, P411
[8]  
MELTZER HY, 1989, J PHARMACOL EXP THER, V251, P238
[9]  
MELTZER HY, 1991, PHARMACOL REV, V43, P587
[10]  
Moore N, 1993, CURR OPIN INVEST DR, V2, P281